MARKET

VNDA

VNDA

Vanda Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.20
-0.35
-2.41%
Pre Market: 14.69 +0.49 +3.45% 09:00 01/25 EST
OPEN
14.43
PREV CLOSE
14.55
HIGH
14.44
LOW
14.00
VOLUME
2.01K
TURNOVER
--
52 WEEK HIGH
15.01
52 WEEK LOW
7.12
MARKET CAP
776.62M
P/E (TTM)
40.40
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Corbus Pharmaceuticals Holdings Inc. stock falls Friday, underperforms market
Shares of Corbus Pharmaceuticals Holdings Inc. tumbled 10.59% to $2.11 Friday, on what proved to be an all-around mixed trading session for the stock market,...
marketwatch.com · 2d ago
Insomnia Pharmacological Treatment Market Research Report by Treatment - Global Forecast to 2025 - Cumulative Impact of COVID-19
New York, Jan 22, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report...
GlobeNewswire · 2d ago
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, outperforms market
Shares of Corbus Pharmaceuticals Holdings Inc. rocketed 35.63% to $2.36 Thursday, on what proved to be an all-around mixed trading session for the stock...
marketwatch.com · 3d ago
Global Insomnia Treatment Drugs Market Analysis By Size, Segments, Applications, Types, Competitors, Demographics And Forecast To 2025
Jan 21, 2021 (The Expresswire) -- "Global Insomnia Treatment Drugs Market"2021 project the value and sales volume of submarkets, with respect to key regions....
The Express Wire · 4d ago
Corbus Pharmaceuticals Holdings Inc. stock falls Tuesday, underperforms market
Shares of Corbus Pharmaceuticals Holdings Inc. slipped 0.57% to $1.73 Tuesday, on what proved to be an all-around great trading session for the stock market,...
marketwatch.com · 5d ago
Insomnia Treatment Market : Analysis and Forecast 2020-2025) -By Product Type, Formulation, and Region
New York, United States, Tue, 19 Jan 2021 05:04:57 / Comserve Inc. / -- The report offers overview of leading companies encompassing their successful...
Comserve · 6d ago
Corbus Pharmaceuticals Holdings Inc. stock remains steady Friday, still outperforms market
Shares of Corbus Pharmaceuticals Holdings Inc. were unchanged Friday, on what proved to be an all-around rough trading session for the stock market, with the...
marketwatch.com · 01/15 22:01
Corbus Pharmaceuticals Holdings Inc. stock outperforms market on strong trading day
Shares of Corbus Pharmaceuticals Holdings Inc. rallied 8.07% to $1.74 Thursday, on what proved to be an all-around rough trading session for the stock...
marketwatch.com · 01/14 22:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VNDA. Analyze the recent business situations of Vanda Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VNDA stock price target is 16.00 with a high estimate of 18.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 249
Institutional Holdings: 67.90M
% Owned: 124.15%
Shares Outstanding: 54.69M
TypeInstitutionsShares
Increased
60
2.93M
New
43
397.75K
Decreased
55
4.11M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.80%
Key Executives
Chairman/Director
H. Thomas Watkins
Chief Executive Officer/President/Director
Mihael Polymeropoulos
Chief Financial Officer/Vice President/Treasurer
Kevin Moran
Senior Vice President/Chief Compliance Officer
Gian Piero Reverberi
Senior Vice President/Chief Compliance Officer
Gianpiero Reverberi
Senior Vice President/Chief Marketing Officer
Joakim Wijkstrom
Senior Vice President/General Counsel/Secretary
Timothy Williams
Senior Vice President
Gunther Birznieks
Other/IR Contact Officer
Aranthan Jones
Independent Director
Phaedra Chrousos
Independent Director
Richard Dugan
Independent Director
Stephen Mitchell
Independent Director
Anne Ward
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About VNDA
Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
More

Webull offers kinds of Vanda Pharmaceuticals Inc. stock information, including NASDAQ:VNDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VNDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VNDA stock methods without spending real money on the virtual paper trading platform.